The field of hematologic oncology has entered a transformative era with the introduction of EPKINLY (epcoritamab), a groundbreaking bispecific antibody that has redefined treatment paradigms for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This innovative therapeutic agent represents the culmination of years of research into harnessing the body’s immune system to combat Read.